# India Vasomotor Symptoms Market

> India Vasomotor Symptoms Market Research Report By Therapy Type (Hormonal, Non-Hormonal) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.38%
- **2024:** $ 160.8 Million
- **2025:** $ 172.67 Million
- **2035:** $ 352 Million
- **Key Players:** Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH)

**Report ID:** MRFR/HC/49996-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-vasomotor-symptoms-market-51754

---

## Market Summary

## **India Vasomotor Symptoms Market Overview**

As per MRFR analysis, the India Vasomotor Symptoms Market Size was estimated at 188 (USD Million) in 2023. The India Vasomotor Symptoms Market Industry is expected to grow from 201(USD Million) in 2024 to 795 (USD Million) by 2035. The India Vasomotor Symptoms Market CAGR (growth rate) is expected to be around 13.315% during the forecast period (2025 - 2035)

**Key India Vasomotor Symptoms Market Trends Highlighted**

The India Vasomotor Symptoms Market is seeing a shift driven by several key factors. One of the primary market drivers is the increasing awareness among women regarding menopause and its symptoms, particularly vasomotor symptoms such as hot flashes and night sweats. Government initiatives aimed at improving women's health are fostering education and outreach, encouraging women to seek help and management options. 

The rising aging population in India also contributes to this demand, as more women are entering the menopausal age. Opportunities in the market are expanding with the growing acceptance of various treatment options, including hormone replacement therapies, herbal supplements, and alternative therapies.

As more healthcare providers recognize the importance of addressing these symptoms, there is room for innovative products and solutions tailored to Indian women's needs, particularly those that consider cultural perceptions and preferences regarding menopause management. Recent trends indicate a surge in the use of digital health platforms that offer telehealth services and e-commerce for women’s health products. This digital shift not only enhances accessibility but also empowers women to manage their symptoms privately and conveniently, reducing stigma. 

Moreover, there is a notable rise in research and development focused on developing targeted therapies to relieve vasomotor symptoms effectively, reflecting a commitment to improving life quality for women in India.Overall, the India Vasomotor Symptoms Market is evolving rapidly, characterized by increased education, innovative solutions, and a more open dialogue about menopause.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Vasomotor Symptoms Market Drivers**

**Increasing Awareness and Diagnosis of Menopausal Symptoms**

Awareness of menopausal health concerns, especially women's vasomotor symptoms, is growing in India. Women's health has been prioritised through campaigns and efforts led by agencies such as the Ministry of Health and Family Welfare, which has increased the number of diagnoses. According to data, vasomotor symptoms during menopause affect about 54% of Indian women. Given that increasing diagnosis rates result in more people seeking treatment, this expanding awareness is essential for the India Vasomotor Symptoms Market Industry. 

The public is now more open to talking about menopause, and reputable medical organisations are releasing more advice. The National Health Mission and other initiatives are encouraging health education, which is anticipated to increase demand for products and treatments in the India Vasomotor Symptoms Market.

**Technological Advancements in Treatment Options**

The India Vasomotor Symptoms Market Industry is experiencing growth due to significant technological advancements in treatment options. Innovations, especially in hormone replacement therapy (HRT) and alternative treatments, are enhancing patient outcomes. According to the Drug Controller General of India (DCGI), the number of approved new drugs related to menopause has increased by 30% over the past five years. 

Such advancements provide physicians with better tools to manage vasomotor symptoms, encouraging more women to seek therapy.Furthermore, collaborations among pharmaceutical companies, like Sun Pharmaceutical Industries and Zydus Cadila, improve the accessibility of effective treatments, supporting market expansion.

**Rise in the Aging Population**

The demographic shift towards an aging population is a significant driver in the India Vasomotor Symptoms Market Industry. According to the Census of India 2011, the population aged 60 years and above was around 104 million, and this number is projected to reach approximately 310 million by 2050. With more women entering menopause each year, the incidence of vasomotor symptoms is expected to rise correspondingly. 

Organizations such as the National Institute on Aging are contributing to research and education about aging, advocating for better health resources.This demographic change creates sustained demand for related therapies and products, representing a robust growth opportunity in the market.

**Increasing Focus on Women's Health**

There is a heightened focus on women's health issues in India, significantly influencing the India Vasomotor Symptoms Market Industry. Public health initiatives and non-governmental organizations are working to put women's health on the national agenda. The government has allocated substantial funds to improve health services for women, including family planning, maternal health, and disease prevention. 

As per the National Health Policy, 2017, there is an emphasis on integrating women's health services into the primary healthcare system.This focus encourages discussions around menopausal health, promoting awareness and improving accessibility to treatments for vasomotor symptoms. Increased investment by the government and various health organizations is expected to directly impact the growth of this market.

**India Vasomotor Symptoms Market Segment Insights**

**Vasomotor Symptoms Market Therapy Type Insights**

The India Vasomotor Symptoms Market portrays a significant growth trajectory, especially in the Therapy Type segment, where it is primarily subdivided into Hormonal and Non-Hormonal therapies. With an increasing awareness of hormonal imbalances due to factors like menopause, the demand for Hormonal therapies remains robust, as these treatments aim to alleviate the discomfort experienced during vasomotor symptoms. Hormonal therapies are often regarded as the frontline treatment option due to their efficacy in providing quick relief from symptoms like hot flashes and night sweats.

They account for a considerable portion of the market, capitalizing on the rising prevalence of conditions associated with hormonal changes among the female population in India, as well as the increasing number of elderly women seeking effective solutions for symptom management. In contrast, the Non-Hormonal treatment segment is gaining traction, reflecting a growing inclination among women to explore alternatives to hormone replacement therapy due to concerns about potential side effects linked to hormonal treatments. 

Non-Hormonal options are also becoming more popular as they offer valid solutions for symptom relief without influencing hormonal levels, thus appealing to a portion of the population that may be hesitant to engage in hormone therapies for various health concerns. As awareness about lifestyle-related health issues improves, the Non-Hormonal segment has started to position itself as a credible alternative, harnessing innovations in pharmaceutical formulations and natural remedies. 

Additionally, cultural factors in India play a significant role in treatment preferences, where women may be more inclined to seek out natural or Ayurvedic Non-Hormonal therapies that align with traditional health practices. The growth of this segment reflects an emerging trend towards personalized medicine and patient-centered care. With an expanding market and competitive landscape, both the Hormonal and Non-Hormonal segments are expected to coexist, providing diverse options for consumers based on individual preferences and health profiles. 

This diversification not only reflects the complexity of patient needs but also underscores the potential for continued growth in the India Vasomotor Symptoms Market, driven by evolving treatment modalities tailored to women’s health.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Vasomotor Symptoms Market Distribution Channel Insights**

The Distribution Channel for the India Vasomotor Symptoms Market represents a crucial aspect of ensuring accessibility and availability of treatment options for individuals suffering from vasomotor symptoms. Among the various channels, Hospital Pharmacies are significant as they cater to a population that requires immediate and specialized treatment, providing medications that may not be available in retail outlets. Retail Pharmacies serve as a vital point of contact for patients in urban and rural areas, enhancing the reach of essential medications to a broader demographic.

The rise of Online Stores has transformed the distribution landscape, offering convenience and anonymity for patients who prefer to manage their health conditions privately. This growing trend aligns with the increasing digital penetration in India and the rise in e-commerce, making it a significant channel. The distribution channel landscape is characterized by diverse dynamics and is essential in addressing the varying needs of the population, contributing to the overall growth of the India Vasomotor Symptoms Market industry.

Expanding these channels while ensuring regulatory compliance can facilitate improved patient access, ultimately addressing the rising demand for treatments in the evolving healthcare ecosystem in India.

**India Vasomotor Symptoms Market Key Players and Competitive Insights**

The competitive landscape of the India Vasomotor Symptoms Market is characterized by the presence of diverse pharmaceutical companies focusing on addressing menopausal symptoms through innovative treatments. This market has gained significance due to the increasing awareness of women's health issues, particularly as they pertain to vasomotor symptoms like hot flashes and night sweats. As the healthcare sector in India expands, several players are striving to enhance their product offerings and market presence. The competition involves not only established pharmaceutical manufacturers but also emerging companies aiming to carve out a niche by offering specialized products and therapies. 

Key factors influencing competition include product efficacy, pricing strategies, regulatory approvals, and distribution channels, leading to a dynamic market environment that is essential for stakeholders to understand.Dr Reddy's Laboratories has established itself as a strong player within the India Vasomotor Symptoms Market through its commitment to research and development, allowing it to create effective medicinal solutions for menopausal symptoms. This company takes pride in its extensive product portfolio, which includes a range of formulations that have been well-received by healthcare practitioners and patients alike. 

The strength of Dr Reddy's Laboratories lies in its robust distribution network and established brand presence across India, which has enabled it to reach a large demographic of women experiencing vasomotor symptoms. Additionally, the company's emphasis on quality and compliance with regulatory standards enhances its reputation among consumers and healthcare professionals, thereby solidifying its position in the market.Merck & Co. also holds a noteworthy presence in the India Vasomotor Symptoms Market, primarily due to its innovative pharmaceutical offerings designed to alleviate menopausal discomfort.

The company offers a selection of key products that aim to address vasomotor symptoms effectively, thereby improving the quality of life for many women in India. 

Merck & Co is recognized for its commitment to research, and this focus has led to strategic collaborations and partnerships that enhance its product development capabilities. In India, the company leverages its extensive experience and knowledge in the women's health segment to build strong relationships with healthcare providers and patients. The company's strengths are further augmented by potential mergers and acquisitions, which aim to expand its market presence and develop a comprehensive portfolio that caters specifically to the needs of the Indian demographic suffering from vasomotor symptoms.

**Key Companies in the India Vasomotor Symptoms Market Include**

**India Vasomotor Symptoms Market Industry Developments**

Recent developments in the India Vasomotor Symptoms Market have indicated a growing interest in innovative therapies and medication. Notable companies such as Dr Reddy's Laboratories, Merck and Co, Abbott India, Bristol-Myers Squibb, Novartis, Sanofi, Johnson and Johnson, Zydus Cadila, Sun Pharmaceutical Industries, Cipla, Lupin Pharmaceuticals, Pfizer, Torrent Pharmaceuticals, Mylan, and Aurobindo Pharma are focusing on expanding their portfolios to address vasomotor symptoms related to menopause. In March 2022, Zydus Cadila launched a novel formulation aimed at alleviating these symptoms, which has been well-received in the market, contributing to overall growth. 

In terms of acquisitions, no significant merger activities have been reported in the last few months; however, the companies are increasingly collaborating for Research and Development initiatives to enhance treatment options. The Vasomotor Symptoms Market in India shows promising growth potential, driven by an aging population and the rising prevalence of menopause-related symptoms. The current market dynamics are reflective of a robust shift towards more personalized healthcare approaches, indicating a strategic movement in the pharmaceutical landscape focused on ensuring better quality of life for women experiencing these symptoms.

**India Vasomotor Symptoms Market Segmentation Insights**

## Market Drivers

### Rising Healthcare Expenditure

The increase in healthcare expenditure in India is a notable driver for the vasomotor symptoms market. As more individuals allocate a larger portion of their income towards healthcare, there is a corresponding rise in the demand for specialized treatments for conditions like vasomotor symptoms. Government initiatives aimed at improving healthcare access and affordability are also contributing to this trend. Reports indicate that healthcare spending in India is expected to reach $370 billion by 2025, which may facilitate greater access to treatments for menopausal symptoms. This financial commitment to healthcare is likely to bolster the vasomotor symptoms market, enabling more women to seek necessary care.

### Growth of the Aging Population

India's demographic shift towards an aging population is a significant factor influencing the vasomotor symptoms market. With projections indicating that by 2030, the elderly population will reach over 300 million, the prevalence of menopausal symptoms is anticipated to rise correspondingly. Older women are more likely to experience vasomotor symptoms, which can severely impact their quality of life. This demographic trend suggests a growing need for targeted therapies and support systems. The vasomotor symptoms market is likely to see increased investment in research and development to cater to this expanding demographic, potentially leading to innovative treatment options tailored for older women.

### Integration of Holistic Approaches

The growing trend towards holistic health approaches is influencing the vasomotor symptoms market in India. Many women are increasingly seeking alternative therapies, such as yoga, acupuncture, and herbal remedies, to alleviate their symptoms. This shift towards integrative health practices suggests a potential market for products and services that combine traditional medicine with modern treatments. The vasomotor symptoms market may benefit from this trend as healthcare providers begin to offer more comprehensive care options that address both physical and emotional well-being. This could lead to a more diverse range of products and services available to women experiencing vasomotor symptoms.

### Advancements in Pharmaceutical Research

Recent advancements in pharmaceutical research are propelling the vasomotor symptoms market forward in India. The development of new medications, including non-hormonal therapies, is providing women with more options to manage their symptoms effectively. Clinical trials and studies have shown promising results for various treatments, which may lead to increased acceptance and usage among women experiencing vasomotor symptoms. The market is projected to grow as these new therapies become available, with estimates suggesting a potential increase in market value by 20% over the next five years. This innovation in treatment options is likely to enhance the overall landscape of the vasomotor symptoms market.

### Increasing Awareness of Menopausal Health

The rising awareness regarding menopausal health among women in India is a crucial driver for the vasomotor symptoms market. Educational campaigns and health initiatives have been instrumental in informing women about the symptoms associated with menopause, such as hot flashes and night sweats. This heightened awareness is likely to lead to increased consultations with healthcare professionals, thereby driving demand for effective treatment options. According to recent surveys, approximately 60% of women in urban areas report experiencing vasomotor symptoms, indicating a substantial market potential. As more women seek solutions, the vasomotor symptoms market is expected to expand significantly, with a focus on both pharmaceutical and non-pharmaceutical interventions.

## Future Outlook

The [Vasomotor Symptoms Market](https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810) in India is projected to grow at a 7.38% CAGR from 2025 to 2035, driven by increasing awareness and innovative treatment options.

**New opportunities:**

- Development of telehealth platforms for remote consultations
- Investment in personalized hormone therapy solutions
- Expansion of over-the-counter treatment options for self-management

By 2035, the market is expected to achieve substantial growth and enhanced accessibility.

## Segment Insights

### By Type: Hormonal (Largest) vs. Non-Hormonal (Fastest-Growing)

The market for vasomotor symptoms in India exhibits a significant share distribution between the hormonal and non-hormonal segments. Hormonal therapies currently dominate the market, taking a substantial portion due to their established efficacy and widespread acceptance among healthcare providers and patients alike. In contrast, non-hormonal treatments are gradually gaining traction, appealing particularly to consumers seeking alternatives without the side effects associated with hormonal options. 

Growth trends within this segment indicate a robust increase in the adoption of non-hormonal therapies driven by rising awareness of menopause management and a growing preference for natural treatment options. The innovation in non-hormonal therapies, such as herbal supplements and lifestyle modifications, adds to their appeal. Additionally, increased focus on women’s health and advocacy for safe treatment alternatives are propelling the growth of the non-hormonal segment, marking a significant shift in treatment paradigms.

Hormonal: Dominant vs. Non-Hormonal: Emerging

Hormonal therapies are well-established in the vasomotor symptoms market, known for their rapid relief from symptoms such as hot flashes and night sweats. These therapies benefit from extensive clinical research that showcases their effectiveness, contributing to their dominant market position. On the other hand, non-hormonal options are emerging as a vital part of the treatment landscape, targeting a niche of patients seeking solutions without the hormonal risks. This segment includes various herbal and natural remedies, which are becoming increasingly popular among women looking for holistic approaches to manage their symptoms. As awareness spreads and product availability increases, non-hormonal therapies are expected to capture a significant share of the market, appealing particularly to health-conscious consumers.

### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Stores (Fastest-Growing)

In the India vasomotor symptoms market, retail pharmacies hold the largest share among distribution channels, representing a significant portion of sales due to their widespread presence and accessibility for patients. Hospital pharmacies also play a crucial role, serving patients directly within healthcare facilities, but retail pharmacies dominate in terms of volume and consumer preference. Online stores, while currently smaller in market share, are rapidly gaining traction as consumers increasingly turn to digital platforms for convenience and availability of products.

The growth trends in this segment are largely driven by the increasing adoption of e-commerce solutions, especially during the aftermath of the pandemic, which has altered consumer buying behaviors. This shift towards online shopping is compounded by the rising awareness of vasomotor symptoms and the need for discreet purchasing options. Retail pharmacies remain strong due to their established trust and service, while online stores are anticipated to emerge as a key player in the market, capitalizing on convenience and technological integration.

Retail Pharmacies (Dominant) vs. Online Stores (Emerging)

Retail pharmacies are established dominants in the India vasomotor symptoms market, owing to their extensive networks and trust among consumers. They provide immediate access to medications and personal consultation, which are essential for managing symptoms effectively. Additionally, retail pharmacies are often located in convenient areas, making them the first choice for many patients. In contrast, online stores are an emerging segment, leveraging technology to cater to the growing demand for convenience and wider product availability. Consumers favor online channels for their ability to maintain privacy and ease of access, which is particularly appealing for sensitive health issues like vasomotor symptoms. The rising integration of digital payment solutions and healthcare apps continues to bolster the growth of this channel, making it a significant part of the market landscape.

## Competitive Benchmarking

The vasomotor symptoms market in India is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key growth drivers include the rising prevalence of menopausal symptoms among women, heightened awareness of treatment options, and the ongoing development of novel therapies. Major players such as Pfizer Inc (US), AbbVie Inc (US), and AstraZeneca PLC (GB) are actively positioning themselves through a combination of research and development initiatives, strategic collaborations, and market expansion efforts. Their collective strategies not only enhance their market presence but also contribute to a dynamic competitive environment that is responsive to evolving patient needs.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in a moderately fragmented market where several players vie for market share. The competitive structure is influenced by the presence of both multinational corporations and local firms, which together create a diverse landscape. The strategic focus on optimizing supply chains and enhancing operational efficiencies is likely to bolster the competitive positioning of these companies in the long term.

In October  Pfizer Inc (US) announced a partnership with a leading Indian healthcare provider to enhance access to its vasomotor symptom treatments across rural areas. This strategic move is significant as it not only expands Pfizer's market reach but also addresses the critical issue of healthcare accessibility in underserved regions, potentially increasing patient adherence to treatment protocols.

In September  AbbVie Inc (US) launched a new digital platform aimed at providing personalized treatment plans for women experiencing vasomotor symptoms. This initiative reflects AbbVie's commitment to leveraging technology to improve patient outcomes and engagement. By integrating AI-driven insights into treatment plans, AbbVie positions itself as a leader in patient-centric care, which may enhance its competitive edge in the market.

In August  AstraZeneca PLC (GB) completed the acquisition of a local biotech firm specializing in innovative therapies for menopausal symptoms. This acquisition is likely to bolster AstraZeneca's product portfolio and accelerate its research capabilities in the vasomotor symptoms segment. The integration of new technologies and expertise from the acquired firm could lead to the development of groundbreaking treatments, further solidifying AstraZeneca's position in the market.

As of November  current trends in the vasomotor symptoms market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence into treatment protocols. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and collaboration. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. Companies that can effectively harness these trends are likely to thrive in an increasingly complex market.

## Recent News & Developments

Recent developments in the India Vasomotor Symptoms Market have indicated a growing interest in innovative therapies and medication. Notable companies such as Dr Reddy's Laboratories, Merck and Co, Abbott India, Bristol-Myers Squibb, Novartis, Sanofi, Johnson and Johnson, Zydus Cadila, Sun Pharmaceutical Industries, Cipla, Lupin Pharmaceuticals, Pfizer, Torrent Pharmaceuticals, Mylan, and Aurobindo Pharma are focusing on expanding their portfolios to address vasomotor symptoms related to menopause. In March 2022, Zydus Cadila launched a novel formulation aimed at alleviating these symptoms, which has been well-received in the market, contributing to overall growth. 

In terms of acquisitions, no significant merger activities have been reported in the last few months; however, the companies are increasingly collaborating for Research and Development initiatives to enhance treatment options. The Vasomotor Symptoms Market in India shows promising growth potential, driven by an aging population and the rising prevalence of menopause-related symptoms. The current market dynamics are reflective of a robust shift towards more personalized healthcare approaches, indicating a strategic movement in the pharmaceutical landscape focused on ensuring better quality of life for women experiencing these symptoms.

## Report Scope

| MARKET SIZE 2024 | 160.8(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 172.67(USD Million) |
| MARKET SIZE 2035 | 352.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.38% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH) |
| Segments Covered | Type, Distribution Channel |
| Key Market Opportunities | Emerging therapies targeting hormonal balance present growth potential in the vasomotor symptoms market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition in the vasomotor symptoms market amid evolving regulatory frameworks. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the India vasomotor symptoms market in 2024?**
A: The market valuation was $160.8 Million in 2024.

**Q: What is the projected market valuation for the India vasomotor symptoms market by 2035?**
A: The projected valuation for 2035 is $352.0 Million.

**Q: What is the expected CAGR for the India vasomotor symptoms market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 7.38%.

**Q: Which companies are considered key players in the India vasomotor symptoms market?**
A: Key players include Pfizer Inc, Bristol-Myers Squibb Company, AbbVie Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd, AstraZeneca PLC, and Novartis AG.

**Q: What were the segment valuations for hormonal and non-hormonal treatments in 2024?**
A: Both hormonal and non-hormonal treatments were valued at $80.4 Million in 2024.

**Q: How do hospital pharmacies compare to retail pharmacies in terms of market valuation for vasomotor symptoms?**
A: In 2024, hospital pharmacies were valued at $40.0 Million, while retail pharmacies were valued at $70.0 Million.

**Q: What is the market valuation for online stores in the distribution of vasomotor symptoms treatments?**
A: The market valuation for online stores was $50.8 Million in 2024.

**Q: What is the anticipated growth trend for the India vasomotor symptoms market?**
A: The market is expected to grow significantly, reaching $352.0 Million by 2035.

**Q: How does the distribution channel impact the overall market for vasomotor symptoms?**
A: Distribution channels like retail pharmacies, valued at $70.0 Million in 2024, play a crucial role in market dynamics.

**Q: What are the implications of the projected CAGR for stakeholders in the India vasomotor symptoms market?**
A: The projected CAGR of 7.38% suggests potential growth opportunities for stakeholders through 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-vasomotor-symptoms-market-51754*